PDGFRA and myeloproliferative disorder: As expected, oral corticosteroids were the most frequently used drug in our series (9/28, 32.1%), except for the five patients with CEL, NOS or M/LN-Eo and PDGFRA rearrangement who were all treated with imatinib, achieving complete hematological remission; furthermore, hydroxyurea was used for cytoreduction in the case diagnosed with MPN-Eo.